Recent patents on endocrine, metabolic & immune drug discovery最新文献

{"title":"Evaluation and Management of Children with Thyrotoxicosis.","authors":"Alexander K C Leung,&nbsp;Alexander A C Leung","doi":"10.2174/1872214812666180327112540","DOIUrl":"https://doi.org/10.2174/1872214812666180327112540","url":null,"abstract":"<p><strong>Background: </strong>Uncontrolled thyrotoxicosis, especially in early infancy, may cause irreversible damage to the central nervous system as well as profound effects on the function of many organs. Thyrotoxicosis has multiple etiologies and treatment depends on the underlying etiology. An accurate diagnosis is essential so that appropriate treatment can be initiated without undue delay.</p><p><strong>Objective: </strong>To review in depth the evaluation, diagnosis, and treatment of children with thyrotoxicosis.</p><p><strong>Methods: </strong>A PubMed search was completed in Clinical Queries using the key terms \"thyrotoxicosis\" and \"hyperthyroidism\". The search strategy included meta-analysis, randomized controlled trials, clinical trials, observational studies, and reviews. Patents were searched using the key terms \"thyrotoxicosis\" and \"hyperthyroidism\" from www.freepatentsonline.com and www.google.com/patents.</p><p><strong>Results: </strong>Graves' disease accounts for approximately 96% of pediatric cases of thyrotoxicosis. Other causes include Hashitoxicosis, toxic adenoma, toxic multinodular goiter, subacute granulomatous thyroiditis, acute suppurative thyroiditis, pituitary thyroid-stimulating hormone-secreting adenoma, pituitary thyroid hormone resistance, iodine-induced thyrotoxicosis, and drug-induced thyrotoxicosis. Familiarity of the clinical features would allow prompt diagnosis and institution of treatment. The underlying cause of thyrotoxicosis should be treated if possible. Treatment options for Graves' disease include antithyroid medications, radioiodine therapy, and surgery. Recent patents related to the management of thyrotoxicosis are discussed.</p><p><strong>Conclusion: </strong>Currently, antithyroid medications are considered to be the initial treatment of choice for Graves' disease in the pediatric age group. Radioactive iodine treatment is generally used for children with poor compliance with antithyroid medications, children not in remission after 1 to 2 years of antithyroid medications, and children with a major adverse effect while receiving an antithyroid medication. Total or near-total thyroidectomy should be considered in children younger than 5 years of age who do not respond to or experience a major adverse effect to antithyroid medications. Surgery should also be considered in those with very large goiter, severe ophthalmopathy, pregnancy, persistent hyperthyroidism in spite of treatment with antithyroid medications and radioactive iodine, and personal preference.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"11 1","pages":"22-31"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35955826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of the World Health Organization in Eliminating Iodine Deficiency Worldwide.","authors":"Paulina Karwowska, Joao Breda","doi":"10.2174/1872214811666170119100715","DOIUrl":"10.2174/1872214811666170119100715","url":null,"abstract":"<p><strong>Background: </strong>Iodine deficiency has been one of the most prevalent micronutrient deficiencies in the world, causing many health disorders, particularly in pregnant women and children. Despite increased salt iodization in some countries and regions, the process has lacked global coordination and sustainability, two prerequisites for reaching the aim of eliminating iodine deficiency. This goal can be reached only by evidence-based, effectively monitored joint and committed actions of all countries.</p><p><strong>Objective: </strong>The aim of the article is to present the role of WHO in leading and coordinating public health actions aiming elimination of iodine deficiency.</p><p><strong>Results: </strong>WHO was given a mandate to coordinate such public health actions, including developing and strengthening relevant public health legislation, issuing technically sound and evidence-based norms and standards, and monitoring the health situation and trends.</p><p><strong>Conclusion: </strong>WHO has coordinated and fostered collaboration between countries, international organizations, scientific associations and non-governmental organization to reach the goal of eliminating iodine deficiency. No recent patents are discussed for this WHO report.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"29 1","pages":"138-142"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82597748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Activities of Red Propolis: A Review.","authors":"Marcia Christina Dornelas de Freitas,&nbsp;Marina Barcelos de Miranda,&nbsp;Daiane Teixeira de Oliveira,&nbsp;Sidney Augusto Vieira-Filho,&nbsp;Rachel Basques Caligiorne,&nbsp;Sonia Maria de Figueiredo","doi":"10.2174/1872214812666180223120316","DOIUrl":"https://doi.org/10.2174/1872214812666180223120316","url":null,"abstract":"<p><strong>Background: </strong>The red propolis (RdProp) is a resin produced by Apis mellifera bees, which collect the reddish exudate on the surface of its botanic source, the species Dalbergia ecastophyllum, popularly known in Brazil as \"rabo de bugio\". Considered as the 13th type of Brazilian propolis, this resin has been gaining prominence due to its natural composition, rich in bioactive substances not found in other types of propolis.</p><p><strong>Objective: </strong>This review aims to address the most important characteristics of RdProp, its botanical origin, the main constituents, its biological properties and the patents related to this natural product.</p><p><strong>Method: </strong>By means of the SciFinder, Google Patents, Patus® and Spacenet, scientific articles and patents involving the term \"red propolis\" were searched until August 2017.</p><p><strong>Results: </strong>A number of biological properties, including antimicrobial, anti-inflammatory, antiparasitic, antitumor, antioxidant, metabolic and nutraceutical activities are attributed to RdProp, demonstrating the great potential of its use in the food, pharmaceutical and cosmetics industries.</p><p><strong>Conclusion: </strong>The available papers are associated to pharmacological potential of RdProp, but the molecular mechanisms or bioactive compounds responsible for each activity have not yet been fully elucidat ed. The RdProp patents currently found are directed to components for the pharmaceutical industry (EP2070543A1; WO2014186851A1; FR3006589A1; CN1775277A; CN105797149A; CN1879859A), cosmetic (JP6012138B2; JP2008247830A; JP6012138B2) and food (JP5478392B2; CN101380052A; WO2006038690A1).</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"11 1","pages":"3-12"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35858563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microdialysis-Assessed Adipose Tissue Metabolism in Critically Ill Patients.","authors":"Ioannis Ilias,&nbsp;Nikitas Nikitas,&nbsp;Maria Theodorakopoulou,&nbsp;Ioanna Dimopoulou","doi":"10.2174/1872214811666170608114933","DOIUrl":"https://doi.org/10.2174/1872214811666170608114933","url":null,"abstract":"<p><strong>Background: </strong>Microdialysis is a minimally invasive technique that allows direct in situ and in vivo sampling, studies and manipulations of the interstitial/extracellular fluid/space. It has been shown to be of use mainly in acute brain injury/neurocritical care.</p><p><strong>Methods: </strong>Microdialysis has been used to study obesity, diabetes mellitus, inflammation and pharmacokinetics at the adipose tissue level. In critically ill patients (and particularly in those with sepsis or septic shock), within days to weeks, adipose tissue shows profound alterations; under such conditions, the implementation of microdialysis can provide researchers with interesting findings.</p><p><strong>Results: </strong>The well-known association between lipolysis and cortisol has been verified at the tissue level with microdialysis. Specific metabolic aberrations in critically ill patients with septic shock have been noted in adipose tissue - assessed with microdialysis before becoming evident in the systemic circulation. Measurement of the lactate to pyruvate ratio in adipose tissue - also assessed with microdialysis - in patients with septic shock has prognostic value equal to that of universally accepted clinical severity scores.</p><p><strong>Conclusion: </strong>Microneedle arrays have been already used to assess interstitial fluid glucose. Possibly, the implementation of microneedle and lab-on-a-chip technology, might complement the current use of microdialysis in the study of the interstitial space/adipose tissue metabolism in health and disease.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"11 1","pages":"32-38"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35072506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects.","authors":"Kuldeep Dhama,&nbsp;Swati Sachan,&nbsp;Rekha Khandia,&nbsp;Ashok Munjal,&nbsp;Hafiz M N Iqbal,&nbsp;Shyma K Latheef,&nbsp;Kumaragurubaran Karthik,&nbsp;Hari A Samad,&nbsp;Ruchi Tiwari,&nbsp;Maryam Dadar","doi":"10.2174/1872214811666170301105101","DOIUrl":"https://doi.org/10.2174/1872214811666170301105101","url":null,"abstract":"<p><strong>Background: </strong>Plants have been known as an integral part of traditional medicine because of their phytoconstituents with their miraculous substances. Tinospora cordifolia (Guduchi/ Giloy) is one such plant having pharmacological functions and medicinal values due to its several constituents such as terpenes, glycosides, alkaloids, steroids and flavonoids. Thus, it has been rightly mentioned in old texts as \"Amrita\".</p><p><strong>Objective: </strong>The objective of the present review is to extend the current knowledge, importance and beneficial pharmacological applications of guduchi in humans for safeguarding various health issues.</p><p><strong>Methods: </strong>We extensively reviewed, analyzed and compiled salient information from the published literature available in PubMed and other scientific databases.</p><p><strong>Results: </strong>The present review describes medicinal applications of T. cordifolia in countering various disorders and usages as anti-oxidant, anti-hyperglycemic, antihyperlipidemic, hepatoprotective, cardiovascular protective, neuroprotective, osteoprotective, radioprotective, anti-anxiety, adaptogenic agent, analgesic, anti-inflammatory, antipyretic, a thrombolytic agent, anti-diarrheal, anti-ulcer, anti-microbial and anti-cancer agent. The plant is also a source of micronutrients viz. copper, calcium, phosphorus, iron, zinc and manganese. A special focus has been made on its health benefits in treating endocrine and metabolic disorders and its potential as an immune booster. Several patents have been filed and granted to inventions encompassing T. cordifolia as a major component of therapeutics for ameliorating metabolic, endocrinal and several other ailments, aiding in the betterment of human life expectancy.</p><p><strong>Conclusion: </strong>The information presented would be beneficial for researchers, medical professionals and pharmaceutical companies to design and develop effective medicines, drugs and healthical products exploiting the multiple as well as specific modes of actions of T. cordifolia, and also help in promoting and popularizing this rich herb having promising potentials to prevent and treat various ailments.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 2","pages":"96-111"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214811666170301105101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34783786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodine Deficiency and Iodine Prophylaxis in Pregnancy.","authors":"Malgorzata Trofimiuk-Mudlner,&nbsp;Alicja Hubalewska-Dydejczyk","doi":"10.2174/1872214811666170309151538","DOIUrl":"https://doi.org/10.2174/1872214811666170309151538","url":null,"abstract":"<p><strong>Background: </strong>Physiological changes in pregnancy result in increased iodine demand, which may not be met in areas of mild-to-moderate iodine deficiency or borderline sufficiency. As a pregnant woman is the only source of thyroid hormones for her child during early gestation, iodine deficiencyinduced hypothyroxinemia may have deleterious effects on fetal development.</p><p><strong>Objective: </strong>To present the current approach to iodine deficiency and its prophylaxis during pregnancy.</p><p><strong>Methods: </strong>A review of the current literature including patents on iodine deficiency in pregnancy has been performed.</p><p><strong>Results: </strong>Negative influence of severe iodine deficiency on fetal development has been proved, and evidence on a deleterious impact of milder forms of iodine deficiency on cognition of the offspring is rapidly growing. Although the WHO has addressed the issues of monitoring iodine status during pregnancy, prophylactic measures and assessment of their effectiveness, there are some controversies, regarding for example the best methods for control of iodine status. New patents in urinary iodine measurement methods may make iodine nutrition monitoring easier. The main method of iodine prophylaxis, in pregnancy also, is universal salt iodization. However, particularly if there is not sufficient coverage of the households with iodized salt, additional measures, such as oral supplementation with potassium iodide tablets, are necessary in pregnant women to provide adequate iodine nutrition. Iodine supplementation improves maternal thyroid function indices; particularly, it prevents goiter formation.</p><p><strong>Conclusion: </strong>Stronger evidence on beneficial effects of iodine supplementation of mild-to-moderate iodine deficient pregnant women on cognitive function of their children is still needed. It may be provided by randomized controlled trials and international initiatives. Changes in the iodine prophylaxis system should be monitored, both to prevent decreased or excessive iodine intake.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 2","pages":"85-95"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34811907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell.","authors":"Vaibhav Sidarala,&nbsp;Anjaneyulu Kowluru","doi":"10.2174/1872214810666161020154905","DOIUrl":"https://doi.org/10.2174/1872214810666161020154905","url":null,"abstract":"<p><strong>Background: </strong>Glucose-stimulated insulin secretion (GSIS) from the pancreatic β-cell involves several intracellular metabolic events which lead to the translocation of insulin granules towards the membrane for fusion and release. It is well established that loss of β-cell function and decreased GSIS underlie the pathogenesis of diabetes. Evidence from several laboratories, including our own, demonstrated requisite roles of Rac1 and phagocyte-like NADPH oxidase (Nox2)-derived reactive oxygen species (ROS) in optimal function of the pancreatic β-cell, including GSIS. However, it is becoming increasingly clear that prolonged exposure of β-cells to hyperglycemic conditions, leads to sustained activation of Rac1-Nox2 signaling axis culminating in excessive generation of intracellular ROS (oxidative stress) and β-cell dysregulation and demise. Such \"cytotoxic\" effects of ROS appear to be mediated via the stress-activated protein kinases/mitogen-activated protein kinases (SAPK/MAPK) signaling pathways.</p><p><strong>Objective: </strong>This review discusses our current understanding of regulation and functions of the conventional MAPKs, namely, ERK1/2, JNK1/2 and p38MAPK.</p><p><strong>Conclusion: </strong>The MAPK pathways are activated in the presence of various stress stimuli including intracellular ROS, via distinct signaling cascades. Once activated, MAPKs participate in specific intracellular signaling processes via interaction with several downstream kinases including the MAPKactivated protein kinases (MAPKAPKs) and transcription factors including c-jun and p53. We have provided an overview of existing evidence in the islet β-cell on the regulatory roles of these MAPKs in mediating cellular responses to alterations in intracellularly generated ROS, which is mediated by the Rac1-Nox2 signaling module. Additionally, we enlisted recent patents developed to improve β-cell function in diabetes and novel pharmacological agents that target oxidative stress and MAPK pathways.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":" ","pages":"76-84"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666161020154905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39979470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodine Prophylaxis in the Lights of the Last Recommendation of WHO on Reduction of Daily Salt Intake.","authors":"Szybinski Zbigniew","doi":"10.2174/1872214811666170608120810","DOIUrl":"https://doi.org/10.2174/1872214811666170608120810","url":null,"abstract":"<p><strong>Background: </strong>In 1994, International Organizations: WHO, UNICEF and ICCIDD indicat ed salt Natrium Chloride as the main carrier of iodine in the prophilaxis systems in the iodine deficient areas over the world. Following this recommendation, 24 European countries introduced the model of iodine p rop hylaxis based on the salt iodization. However in 7 European countries only - among tchem in Poland - salt iodization is mandatory as the most effective mode lon the population level.</p><p><strong>Objective: </strong>Presenting the method for the reduction of the consumption of iodized salt and supplement ation of iodine by other iodine carriers.</p><p><strong>Methods: </strong>Concentration of iodine in the salt has been calculated according to the daily salt consumption and WHO recommendation on the daily dose of iodine that should be supplied in different groups of age and in pregnant and breast feeding women. No relevant recent patents were available for this WHO report.</p><p><strong>Results: </strong>Consumption of salt in European countries is from 8 to 11g/day/person. In Poland, it is very high 11.5g/day/person. WHO in 1996 introduced recommendation on reducing daily salt intake to 5g/day/person as Natrium is a risk factor of hypertension and some neoplastic processes.</p><p><strong>Conclusion: </strong>When iodized salt is the main carrier of iodine in the prophylaxis systems, additional carriers of iodine should be introduced in the food market for instant -iodized mineral water. A very important factor is the proper information and education on the population level. This action is under control of the Polish Council for Control of Iodine Deficiency Disorders [PCCIDD] established in 1991 following the example of the International Council for Control of Iodine Deficiency Disorders [ICCIDD].</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"11 1","pages":"39-42"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35072507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of the Iodine Global Network in Elimination of Iodine Deficiency.","authors":"John H Lazarus","doi":"10.2174/1872214811666170330152202","DOIUrl":"https://doi.org/10.2174/1872214811666170330152202","url":null,"abstract":"BACKGROUND Iodine deficiency (ID) is a major cause of brain damage if not corrected in early pregnancy. Even mild ID leads to measurable neurointellectual impairment. The iodine global network (IGN), previously the international council for the control of iodine deficiency disorders (ICCIDD), has achieved remarkable progress in facilitating iodine nutritional sufficiency in about 70-80% of countries in the world during the past 3 decades or so. RESULTS At present there are 25 countries with documented iodine deficiency. However, there are still many countries, especially in Europe, with mild iodine deficiency which require active interventional strategies to ensure adequate iodine nutrition. In this context, rigorous monitoring of iodine status is essential to ensure adequate iodisation. CONCLUSION The IGN, with 10 world-wide regional coordinators and 100 national coordinators is well placed to implement appropriate strategies to achieve these goals. The recent award of a Horizon 20/20 grant to European stakeholders to harmonise iodine supply in Europe emphasises the commitment of the EU to make improvement in the global iodine health. There are no relevant recent patents for this report.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 2","pages":"119-122"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34877511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Use and Patentability of Cord Blood.","authors":"Turker Cavusoglu,&nbsp;Kubilay Dogan Kilic,&nbsp;Gurkan Yigitturk,&nbsp;Canberk Tomruk,&nbsp;Mehmet Turgut,&nbsp;Yigit Uyanikgil","doi":"10.2174/1872214812666180314121241","DOIUrl":"https://doi.org/10.2174/1872214812666180314121241","url":null,"abstract":"<p><strong>Background: </strong>The blood in the umbilical cord that provides the connection between mother and fetus during pregnancy is called cord blood. The blood of umbilical cord which is usually got rid of following birth, is a very rich stem cell source.</p><p><strong>Objective: </strong>Cord blood collection gives no harm to the mother and baby. Besides, its allogeneic and autologous usage, the most important disadvantage is that the number of cells is insufficient in adults.</p><p><strong>Conclusion: </strong>Today, it is predominantly used for therapeutic purposes for many diseases. The aim of this review is giving a detailed information about groups of stem cells in cord blood and determining the point of clinical use.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"11 1","pages":"13-21"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35916567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}